• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Stocks

A Look at Mylan's New Post-Merger Management

What new management means for Mylan shareholders moving forward.
By KEVIN CURRAN Jul 29, 2019 | 11:43 AM EDT
Stocks quotes in this article: MYL, PFE

Mylan's (MYL) combination with the world's largest drug maker, folding into Pfizer's (PFE) Upjohn business, is not only a big shakeup for the business, but for management.

Bresch Bows Out

As part of the deal, current Mylan CEO Heather Bresch will be departing her role and will be replaced by Pfizer's Michael Goettler, the current head of Upjohn.

A company biography details an extraordinary rise to power for Bresch, who began her career at Mylan as a data entry clerk in 1992. After 20 years climbing the ladder, she rose to become CEO, the first female to head a global pharma company of its size.

"During her almost three-decade tenure at Mylan, Heather has been instrumental in transforming the company from a 300 employee, $100 million revenue, single-country operation into a global organization that, upon close of the Mylan and Upjohn transaction, will have more than 45,000 employees, nearly $20 billion in revenue and a reach across more than 165 countries, including a new leading position in China," board chair Robert Coury said. "On behalf of Mylan's Board, I extend tremendous thanks and credit to Heather Bresch for her many years of service to Mylan and for her authentic leadership style that helped to ensure Mylan's mission of access could live on for years to come."

Still, many analysts on Wall Street and Capitol Hill are likely happy to see her go, as her tenacious defense of drug prices, particularly the EpiPen, has been a sore spot for the stock and the company's public image in recent years.

Additionally, her substantial salary hikes have caught the ire of many progressive politicians looking to police soaring prices.

"This hearing is critical because yet another drug company, Mylan, has jacked up the price of a lifesaving product for no discernible reason... I did read your testimony, Ms. Bresch, and I was not impressed," Rep. Elijah Cummings (D-MD) said in a hearing in 2016. "The reason being, I believe, is to get filthy rich at the expense of our constituents."

The excoriation at the hands of Cummings continued through a number of hearings, some of which Bresch began to skip.

Congress made clear its displeasure with Bresch's continued pay hikes, bringing her compensation to near the top of her industry from a previously quite low level.

With a parting shot, Bresch will carry a handsome payout into retirement.

$MYL CEO Heather Bresch may be leaving post-combo w $PFE Upjohn, but not empty-handed. Per Wells Fargo's @davidmaris note: "According to Mylan's proxy filed May 24, 2019, in a change in control, Mylan's CEO would receive approximately $37.6 million."

— Meg Tirrell (@megtirrell) July 29, 2019

CFO Ken Parks will also be departing the company after a considerably shorter tenure, beginning in 2016.

Goettler's Got the Job

With the new company again being  U.S. domiciled, a new European CEO will come in to head the unit in place of Bresch.

Michael Goettler, the new man atop the combined totem pole, brings experience as Group President of Pfizer's Upjohn business prior to the deal, with previous experience as Global President of Rare Diseases for Pfizer's Global Innovative Pharma Business.

Goettler moved to his current role from Wyeth Pharmaceutical, which was acquired by Pfizer in 2009. Following the deal, he was appointed president of the company's Asia-Pacific region for Specialty Care subsequently,  bounced from executive titles including Global Commercial Officer and regional president of Europe for Specialty Care.

His global focus is of particular interest to analysts and investors who are eager for Mylan's gaze to turn away from its domestic shores.

"I'm honored by the opportunity to lead this new company, which will deliver more medicines to more patients across the globe. I'm also excited to combine two talented and deeply experienced teams that share a passion for providing patients with access to medicines," Goettler said upon his appointment. "I look forward to delivering on that shared commitment by combining Mylan's broad and diverse portfolio with Upjohn's iconic, trusted brands and bringing the Mylan growth products to the Upjohn growth markets."

The focus on growth markets could accelerate upside from the deal, according to bullish analysts.

"[Mylan] could benefit from operating synergy and OUS diversification, as well as a management overhaul," Leerink Partners analyst Ami Fadia said. "Michael Goettler as the new CEO [will] probably take a fresh look at Mylan's pipeline and clarify the strategic focus for the combined company."

Malik Not Moving

In one interesting nugget, the new company will maintain the president's role of Rajiv Malik, who is also a board member at the company.

"I am also pleased that Rajiv Malik will continue to serve in the role of president," Coury said. "Rajiv has been and continues to be instrumental in the building and execution of our true one-of-a-kind and very complex platform, and he will serve as a strong complementary partner to Michael [Goettler]."

Malik's sustained role is particularly interesting given the hostile headlines that have been aimed at him as of late, much the same as Bresch's battering.

Malik, who faces massive civil suits for alleged drug price fixing, had been supposed to be another exit from the new firm, but instead will stay on.

It will be interesting to observe how his role evolves as the deal comes close to close and all the shakeups shake out.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are restricted from trading individual securities.

TAGS: Mergers and Acquisitions | Regulation | Restructuring | Executive compensation | Investing | Stocks | Biotechnology | Pharmaceuticals | Emerging Markets (South America, Asia, Middle East) | Stock of the Day

More from Stocks

Alibaba Shares Skyrocket in Hong Kong on Restructuring Plan

Alex Frew McMillan
Mar 29, 2023 8:00 AM EDT

The company will split into six separate entities which will be run under separate management and free to list independently.

I Wouldn't Plow Ahead With Buying Deere Despite an Analyst's Thumbs Up

Bruce Kamich
Mar 29, 2023 7:50 AM EDT

The technical picture of the farm equipment giant simply isn't encouraging.

Bank Regulations, Treasuries, Dwindling Trading Volumes, AMC, Amazon, Lockheed

Stephen Guilfoyle
Mar 29, 2023 7:26 AM EDT

These banking system steps would place increased drag on the velocity of money, which in turn will suppress economic growth.

The Bulls Are Trying Again, But Economic Uncertainty Will Keep Things Choppy

James "Rev Shark" DePorre
Mar 29, 2023 6:48 AM EDT

It's very messy action, and the primary reason for it is that there is a high level of uncertainty about where interest rates are heading.

What Goes Up in the Market, Doesn't Always Go Down in a Straight Line

Helene Meisler
Mar 29, 2023 6:00 AM EDT

Let's examine how once-hot bull market stocks can fall in a bear market, and why it's no time for complacency.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 04:00 PM EDT CHRIS VERSACE

    AAP Podcast: This Solar Company Is a Head-Turner

    Listen to my interview with Brian Roth, CEO of sol...
  • 01:56 PM EDT PETER TCHIR

    Very Cautious

    I am very cautious here. I don't like how the c...
  • 08:58 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    How to Adjust Your Trading Style as Market Conditi...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login